Supply
LEQEMBI® injection is a preservative-free, sterile, clear to opalescent, and colorless to pale yellow solution. LEQEMBI is supplied in single-dose vials per carton as follows1:
![LEQEMBI 200-mg vial LEQEMBI 200-mg vial](/-/media/Project/EIsai/LeqembiHcp/Treat-and-Monitor/Supply-information-and-additional-considerations/200-mg-vial.jpg?h=227&iar=0&w=264&hash=384D0A64F5BF52CBD2EA0C2506EB3422)
200 mg/2mL (100 mg/mL)
Single-dose vial with dark grey flip cap NDC 62856-212-01
![LEQEMBI 500-mg vial LEQEMBI 500-mg vial](/-/media/Project/EIsai/LeqembiHcp/Treat-and-Monitor/Supply-information-and-additional-considerations/500-mg-vial.jpg?h=227&iar=0&w=264&hash=3B24CC79FABD8154A86921019DE56F6A)
500 mg/5mL (100 mg/mL)
Single-dose vial with white flip cap NDC 62856-215-01
![Specialty distributor guide thumbnail image Specialty distributor guide](/-/media/Project/EIsai/LeqembiHcp/Treat-and-Monitor/Supply-information-and-additional-considerations/specialty-distributor-guide.png?h=165&iar=0&w=126&hash=343AC0415281DDAD3155AEDED67CC4B5)
To reorder LEQEMBI, contact your specialty distributor
Storage and handling1
![Unopened vial icon Unopened vial icon](/-/media/Project/EIsai/LeqembiHcp/Treat-and-Monitor/Supply-information-and-additional-considerations/unopened-vial-icon.png?h=112&iar=0&w=71&hash=8531980DB5D50DA739EAE904A8626989)
Unopened vial
Store in refrigerator at 2°C to 8°C (36°F to 46°F)
Store in the original carton to protect from light
Do not freeze or shake
![Diluted solution icon Diluted solution icon](/-/media/Project/EIsai/LeqembiHcp/Treat-and-Monitor/Supply-information-and-additional-considerations/diluted-solution-icon.png?h=140&iar=0&w=34&hash=DE850045285A38F52D09AC8827BCE138)
Diluted solution
After dilution, immediate use is recommended
If not administered immediately, store LEQEMBI refrigerated at 2°C to 8°C (36°F to 46°F) for up to 4 hours, or at room temperature up to 30°C (86°F) for up to 4 hours. Do not freeze
Use in specific populations1
![Pregnant women icon No adequate data on LEQEMBI use in pregnant women](/-/media/Project/EIsai/LeqembiHcp/Treat-and-Monitor/Supply-information-and-additional-considerations/no-adequate-data-on-LEQEMBI-use-in-pregnant-women-icon.png?h=96&iar=0&w=52&hash=FF4A374C7E2DD89FFB24B741232DCAE7)
There are no adequate data on LEQEMBI use in pregnant women, women who are breastfeeding, or pediatric patients.
![Geriatric population icon Data on geriatric population](/-/media/Project/EIsai/LeqembiHcp/Treat-and-Monitor/Supply-information-and-additional-considerations/data-on-geriatric-population-icon.png?h=100&iar=0&w=43&hash=3AC2A62FB50FBC2625585FE866439515)
For the geriatric population, in Study 1 and Study 2, the age of patients exposed to LEQEMBI 10 mg/kg every 2 weeks ranged from 50 to 90 years, with a mean age of 72 years; 81% were 65 years and older, and 39% were 75 years and older. No overall differences in safety or effectiveness of LEQEMBI have been observed between patients 65 years of age and older and younger adult patients.